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ABSTRACT
Aim To estimate annual societal costs associated with 
chemotherapy for early breast cancer in the UK.
Design Mixed methods: (a) an incidence- based cost- 
of- illness model was developed of indirect costs in 
patients with breast cancer and carers, and estimated 
from diagnosis through active treatment until death; (b) 
interviews with stakeholders were also undertaken to 
understand actual experiences and impacts of these costs.
Data sources Model data were collated from relevant 
national data sources covering general population 
statistics, UK cancer registries, clinical guidelines and 
published literature, and patient survey data. Patient 
and staff views were collected through semistructured 
interviews.
Participants Model: patients with early breast cancer 
receiving systemic anticancer therapy in the UK. Interviews 
were undertaken with women who had chemotherapy and 
medical practitioners involved in breast cancer care.
Results Total costs of chemotherapy in the UK economy 
are over £248 million. Societal productivity losses amount 
to £141.4 million, which includes £3.2 million associated 
with premature mortality, short- term and long- term work 
absence (£28.6 million and £105 million, respectively). 
£3.4 million is associated with mortality losses from 
secondary malignancies due to adjuvant chemotherapy. 
A further £1.1 million in lost productivity arises from 
informal care provision. Out- of- pocket costs per round 
of chemotherapy account for £4.2 million, or an annual 
average of almost £1100 per patient. Interview findings 
support the cost burden modelled and also highlight the 
impact on cognitive function of patients and how this 
could increase the cost burden to patients, their families 
and wider society. In addition, estimated costs for carer 
emotional well- being are £82 million in lost quality of life.
Conclusion Chemotherapy use carries significant indirect 
costs for society, as well as patients and their carers. 
These wider costs and societal perspective should be 
considered by commissioners to ensure chemotherapy 
is better targeted at those who most need it and to avoid 
placing unnecessary costs on patients, their caregivers 
and wider society.
BACKGROUND
Breast cancer is the most common cancer 
in women and second most common 
cancer overall with 2 million cases per year 
worldwide.1 In the UK, annual new cases 
and deaths number approximately 55 000 
and 11 563, respectively; 76% survive breast 
cancer for 10 or more years.2 Patients with 
invasive breast cancer will be treated with 
surgery followed by breast reconstruction. 
Most patients will require adjuvant therapy 
using radiotherapy, chemotherapy, endo-
crine therapy or a combination of these to 
reduce the risk of recurrence.3 Based on treat-
ment breakdowns provided by the National 
Cancer Registration and Analysis Service 
(NCRAS), 63% and 34% of breast cancer 
cases diagnosed in England in 2013–2015 
received radiotherapy and chemotherapy, 
respectively.4
Direct treatment costs, including costs asso-
ciated with adjuvant chemotherapy acquisi-
tion, delivery and toxicity, are estimated to 
be £3145 per patient for the entire chemo-
therapy regimen.5 Several studies have exam-
ined the wider economic burden of cancer,6 7 
including breast cancer.8 9 However, estimates 
are lacking for the societal economic burden 
specifically associated with chemotherapy 
use for early breast cancer. We address this 
gap by taking an incidence- based modelling 
approach to estimate total costs to patients, 
caregivers and wider society associated with 
chemotherapy use for early breast cancer in 
the UK. We also sought the views of patients 
and healthcare practitioners to explore and 
convey the context and experience of these 
costs.
Strengths and limitations of this study
 ► First study to comprehensively assess non- health 
care costs associated with chemotherapy for early 
breast cancer.
 ► Inclusion of personal experience provided a valuable 
humanist approach to complement the study.
 ► The model is limited by the availability and reliability 
of relevant data (no actual patient- level data).
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METHOD
Patient and public participation
Patients and members of the public were not involved in 
the design and conduct of this study.
Model: target population and time horizon
We estimated costs for male and female patients aged 20 
years and over in the UK diagnosed with early breast cancer 
in 2018–2019 and receiving systemic anticancer therapy 
(SACT). We used International Statistical Classification of 
Diseases and Related Health Problems–10th Revision (ICD-
10) diagnosis codes10 C50 (malignant neoplasm of breast) 
and D05 (breast cancer in situ). We included patient and 
carer costs incurred up to 1 year following chemotherapy 
and productivity losses for the cohort’s life span.
Model: overall approach
We developed an incidence- based cost- of- illness (COI) 
model in MS Excel (see figure 1 and online supplemental 
table A for model framework) to estimate non- treatment 
costs to patients/carers/society in the following categories:
 ► Patient and caregiver costs comprising out- of- pocket 
payments and the emotional burden of caregiving.
 ► Societal productivity losses due to:
1. Caregivers’ time spent on informal care provision 
(short- term losses, up to 1 year, were included to cap-
ture the impact of caregiving only for the duration 
that patients received chemotherapy). We made this 
assumption so as to avoid overestimating the produc-
tivity losses.
2. Patients’ short- term work absence due to treatment.
3. Patients’ long- term work absence as a result of inability 
to return to work.
4. Patients’ early mortality due to chemotherapy.
5. Patients’ secondary mortality due to chemotherapy- 
related secondary malignancies.
We took a ‘bottom up’ approach for costings and 
followed the Larg and Moss11 checklist for critically eval-
uating COI studies. Societal productivity losses (informal 
care; short- term and long- term work absence; early and 
distant mortality) were valued using the human capital 
approach. Informal care was additionally valued from 
the caregiver perspective using published estimates and 
shadow pricing for carers’ emotional burden. The latter 
being a novel approach, we did not include this cost in 
the total costs. We also outline treatment costs falling to 
the health service for context.
Model: inputs and analyses
A series of focused searches was conducted to identify 
relevant data. Model inputs are summarised in table 1 
and detailed in online supplemental tables A–F.
Incidence
Country- specific breast cancer incident cases were estimated 
for ICD-10 codes C50 and D05 by combining population 
estimates with relevant age- specific and gender- specific inci-
dent cases from relevant national cancer registration statis-
tics: Office for National Statistics–England,12 Information 
Services Division–Scotland,13 Welsh Cancer Intelligence and 
Surveillance Unit–Wales14 and Northern Ireland Cancer 
Registry.15 The number of patients with early breast cancer 
receiving chemotherapy for curative intent was then esti-
mated by applying national percentages of relevant tumours 
diagnosed (breast, breast in situ) and receiving chemo-
therapy, obtained from NCRAS and the UK and Ireland 
Association of Cancer Registries.4 16
Mortality/survival
Early mortality losses were estimated for patients who 
died within 30 days of SACT (any cytotoxic chemo-
therapy; active anticancer therapies such as monoclonal 
Figure 1 Overall framework for the cost- of- illness model. Items labelled 1–12 in figure 1 above are described in further detail 
in online supplemental table A. *Costs associated with the emotional burden of caregiving are indicative only and are excluded 
from the estimate of total costs.
copyright.












pen: first published as 10.1136/bm




3Parsekar K, et al. BMJ Open 2021;11:e039412. doi:10.1136/bmjopen-2020-039412
Open access
Table 1 Inputs table
Description Input Reference
Incidence and no of early breast cancer cases in the UK
  England Office for National 
Statistics (ONS). Cancer 
registration statistics, 
England12
  Scotland Information Services 
Division Scotland13
  Wales Welsh Cancer Intelligence 
and Surveillance Unit14




34% Cancer Research UK, 
NCRAS, UKIACR; (*age 
and country- specific 
estimates used where 
possible)2 4 16
30- day mortality in chemotherapy- treated cases
  <50 years 0.03% 30- day mortality after 
receiving SACT in 
England, 2015–2016 
(curative intent) SACT 
dataset17 ; smoothing 
across age categories was 
not undertaken
  50–69 years 0.28%
  70+ years 0.54%
Cost inputs
Carers
  Total no of breast 
cancer carers for 
patients undergoing 
chemotherapy
1967 *Estimated using UK 
population estimates32 and 
statistics from Macmillan 
UK26
  No of hours of 
employment lost by 
carer (weekly)
2.18 Round et al9
  Weighted median wage 
of carer (per hour)
£9.21 *Estimated using median 
hourly wage a report in 
ASHE table 6, ONS19
Weighted by profile of 
cancer carers’ working 
status YouGov and 
Macmillan Cancer 
Support26
  Disposable household 
income/year
£19 834 Gross disposable 
household income from 
ONS33
  Coefficient for caring 
for other member who 
had an accident within 
last year and can still do 
daily activities
0.138 McDonald and 
Powdthavee.28 We 
have assumed these 
coefficients apply to 
cancer caregivers
  Coefficient for impact 
on real equivalent 
household income
0.089
Patient out- of- pocket expenses
Travel to and from appointments
  Mean travel cost per 
week
£31 *Calculated for the 
duration of chemotherapy 
only. Estimated from 
monthly costs reported in 
Macmillan UK29
  Probability of incurring 
outpatient travel cost
69%
  Mean parking cost per 
week
£7






  Probability of receiving 
OTC/prescription 
medications
22% *Costs were extrapolated 
to annual values based 
on estimates provided in 
Macmillan UK29
  Mean OTC medication 
cost per year
£104.30
  Probability of receiving 
dietary supplements
12%
  Mean cost of dietary 
supplements per year
£208.60
  Probability of receiving 
private treatment for 
healthcare
4%
  Mean annual cost of 
private treatment for 
healthcare
£330
  Probability of receiving 
personal care at 
person’s home
5%
  Mean annual cost 
of personal care at 
person’s home
£139
Others—daily living (monthly costs)
  Food and drink £28.65 Macmillan UK29
  % affected—food and 
drink
22
  Home help £37.47




  % affected—childcare 1
Other—clothing, hair wigs 
(monthly cost one- off)
  Wigs, hairpieces £25.35
  % affected—wigs, 
hairpieces
10
  Fabric supports £15.43
  % affected—fabric 
supports
5
  Clothing £34.16
  % affected—clothing 29
Healthcare
Direct costs for adjuvant 
chemotherapy per regimen
£5504 Costs associated with 
adjuvant chemotherapy 
acquisition, delivery and 
toxicity £3145/course5
Additional inputs
  Discounting 3.5% NICE34
  Wage growth 3.50 ONS22
  Life expectancy at 
birth—females (UK)
82.86 years ONS 201835
  Life expectancy at 
birth—males (UK)
79.18 years
  Inflation indices various ONS—inflation indices,36 
PSSRU 201837
  Wage rates various ONS. Earnings and hours 
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antibodies, for example, trastuzumab; targeted biological 
treatments such as estimated glomerular filtration rate 
tyrosine kinase inhibitors). The 30- day mortality outcome 
included death from all causes, including iatrogenic 
deaths or those due to disease progression. The national 
30- day mortality rates post- SACT were derived from the 
SACT Chemotherapy Dataset– England,17 and applied to 
newly diagnosed patients receiving chemotherapy with 
curative intent. The same proportion was applied to the 
target population from Scotland, Wales and Northern 
Ireland.17 Given limited relevant data, estimates for 
longer term mortality were narrowed in scope to only 
include mortality due to two potential secondary malig-
nancies—acute myeloid leukaemia and myelodysplastic 
syndrome.18
Resource use and costs
National estimates for age- specific and gender- specific 
wages, labour market participation, employment and 
wage growth were applied to productivity and mortality 
losses.19–22 Days off work, patient out- of- pocket expenses, 
direct treatment costs and informal care quantities and 
costs were obtained from published literature. Estimates 
for the value of the emotional burden of caregiving were 
obtained from a published analysis of impacts on carers 
of accident victims; we have assumed the same estimated 
coefficients here for cancer carers. Where estimates were 
unavailable, relevant assumptions were made and tested 
using sensitivity analyses. This included adjustments to 
published estimates of patient- related costs due to travel 
and parking for hospital visits which varied by chemo-
therapy regimen, other out- of- pockets including over- 
the- counter medications, dietary supplements, use of 
private healthcare, home care, wigs, clothing and so on. 
Additional sensitivity analyses were performed to address 
uncertainty in incidence of secondary malignancy rates 
following chemotherapy.
Model: outputs
Costs were estimated in terms of total annual cost and 
average annual cost per patient, with averages calculated 
for relevant subgroups rather than the total target popu-
lation. All costs are in 2018 British Pounds Sterling (£). 
Future costs were discounted at 3.5%.
Participant interviews: sample and measures
Two women who had experienced breast cancer, their 
main carers, and two healthcare practitioners were iden-
tified and invited to participate in the study by a cancer 
charity. The carers declined because the experience 
would be too emotionally painful; all others agreed and 
participated in semistructured interviews covering rele-
vant topics (table 2). Pseudonyms are used throughout to 
protect anonymity.
Participant interviews: procedure
Participants received an invitation letter, information 
sheet and consent form. Interviews were conducted by 
two researchers (SHW and KP) from the University of 
East Anglia, lasted about 1- hour long and were audio 
recorded. Interviews with Mary and Sue were scheduled 
by the cancer charity and conducted in a room in one of 
their centres. The interview with Mary was face- to- face. 
Description Input Reference
  Labour force 
participation rate
various ONS. Labour market 
participation rates by age 
and sex, UK, 1995, 2005, 
2015, 201720
  Employment rates various ONS. Table A05: labour 
market by age group: 
women by economic 
activity and age 
(seasonally adjusted)21
  Paid hours various ONS. Paid hours: Table 
6.10a ASHE 201819
  Age- specific and age- 
standardised relative 
survival for acute 
myeloid leukaemia
various ECIS database18
*Costs were calculated separately. Detailed estimation in online supplemental table B.
ASHE, Annual Survey of Hours and Earnings; ECIS, European Cancer Information 
System; NCRAS, National Cancer Registration and Analysis Service; NICE, National 
Institute for Health and Care Excellence; ONS, Office for National Statistics; OTC, 
over- the- counter; PSSRU, Personal Social Services Research Unit; SACT, systemic 
anticancer therapy; UKIACR, UK and Ireland Association of Cancer Registries.
Table 1 Continued
Table 2 Demographics of participants and the topics covered in their interviews
Participants Topics covered
Women who had suffered breast cancer  ► Physical and emotional impacts of the patient’s 
chemotherapy on themselves and their family
1. Mary (60–70 years). Her main carer was a daughter who 
suffered from irritable bowel disease and had four children 
(aged 8–24 years).
 ► Own cost implications of chemotherapy (eg, loss of 
earnings, the cost of wigs, travel, parking)
2. Sue (40–50 years) had two children (aged 15–25 years). Her 
husband worked away from home during the week.
 ► Others’ cost implications of chemotherapy (eg, loss of 
earnings by carers, childcare)
Healthcare practitioners  ► Their role with patients
1. A nurse who supported women suffering breast cancer.  ► Level of risk from chemotherapy treatment
2. A consultant surgeon for breast cancer at a large hospital in 
England.
 ► Effect and cost of chemotherapy treatment for patients
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The interview with participant Sue was by telephone. 
After the interview, each participant was debriefed and 
offered support by the cancer charity counselling services. 
Interviews with healthcare practitioners were conducted 
face- to- face.
Participant interviews: data analysis
Interviews were transcribed verbatim, anonymised and 
validated with each participant. Transcripts were themati-
cally analysed and organised according to key themes and 
concepts of the study: effects of diagnosis and treatment; 
impact on family; work arrangements and other direct 
costs.
RESULTS
Total patient and societal productivity costs
Total productivity losses, out- of- pocket costs and 
caregiver- related non- health care costs were estimated at 
£145.4 million, outweighing the £102.7 million associated 
with direct treatment costs. This does not include the 
potential impact of emotional well- being of carers.
Patient and caregiver costs
Out- of- pocket expenses (table 3) during a round of 
chemotherapy treatment were £4.2 million. These were 
dominated by travel costs of £2.7 million (61%) which 
varied by number of hospital visits (3–12 weeks/cycles) 
depending on the chemotherapy regimen (3–12 visits 
considering a chemotherapy regimen up to 9–12 weeks, 
with docetaxel every 3 weeks; or weekly/biweekly pacli-
taxel). Results from associated sensitivity analyses are 
reported in online supplemental table F.
Emotional well- being impacts on carers were valued 
at ~£82 million. This imputed compensating income 
required for the provision of informal care, for a patient 
who can still perform daily activities, was estimated at 
~£74 000 per person per year. For high dependency 
patients who cannot perform daily activities, the esti-
mated compensation required is much higher at ~ 
£124 000 (total cost: £138 million/year).
Productivity losses
Patient productivity losses totalled ~£140 million (£101 
200 per person) (table 4) and were dominated by long- 
term (75%) and short- term (21%) work absences.
Short- term work absence comprised:
 ► An estimated 7481 people undergoing adjuvant 
chemotherapy for early breast cancer (employed and 
participating in the workforce in 2017–2018, with the 
exception of Wales, which was based on 2016 inci-
dence statistics).
 ► Approximately 320 000 lost workdays while under-
going a chemotherapy regimen (10 weeks).
 ► An average of 39–51 days off work to undergoing 
chemotherapy treatment.
These base case findings were based on a standard 
chemotherapy regimen lasting up to 10 weeks. Alternative 
estimates for 9- week and 12- week regimens are provided 
in table 5.
Estimates for long- term work absence suggested that:
 ► Approximately 5253 people (employed and partici-
pating in the UK workforce in 2017–2018, with the 
exception of Wales, which was based on 2016 inci-
dence statistics) are unable to return to work over 
Table 3 Out- of- pocket expenses during a round of chemotherapy treatment
Out- of- pocket expenses Total costs, £ (%) Costs/patient (£)
Travel to and from appointments 2 700 000 (57) 188 (based on 6 treatment visits)
Parking 289 372 (7) 41 (based on 6 treatment visits)
Dietary supplements 467 206 (11) 209
Over- the- counter medicines 428 272 (10) 104
Private healthcare treatment 221 733 (6) 330
Personal care at person’s home 129 717 (3) 139
New clothes 184 897 (5) 34
Wigs and hairpieces 47 314 (1) 25
Fabric supports 14 400 (<1) 15
Total 4 223 538 1085
Table 4 Total patient productivity losses
Patient productivity losses Total cost (average per person)
30- day mortality cost following chemotherapy £3.2 million (£64 000)
Short- term work absence: time taken off work due to chemotherapy ~£28.7 million (~£300 500)
Long- term work absence: inability to return to work ~£105 million (~£32 000)
Secondary malignancies: 30- day mortality following chemotherapy £3.4 million (£64 000)
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3 years thereby resulting in a loss of ~£105 million 
(~£33 000 per person).
 ► Considering the working age population (<65 years), 
the 3- year productivity loss is £93 million based on 
an estimate that 17% are unable to return to work 
following adjuvant chemotherapy.23
There were an estimated 48 chemotherapy- related 
deaths for all breast cancers in 2018 in the UK with a total 
loss of 930 life years, amounting to total early mortality 
costs of £3.2 million. Among these, nearly 50% (n=23) 
were of working age (<65 years) with an estimated loss of 
630 life years due to chemotherapy- related early mortality. 
Chemotherapy- related early mortality led to an estimated 
average productivity loss of £65 000 over the lifetime. 
This was weighted for differences in mortality rates by 
sex, resulting in higher estimates for men (£98 000 vs 
£65 000) due to differential wage rates and hours. In 
addition, 0.5% of cases develop secondary malignancies 
5 years after receiving chemotherapy.24 We estimate asso-
ciated productivity losses at ~£3.4 million (£50 000/per 
person). Five- year relative survival was used to estimate 
overall death rate following development of secondary 
malignancies.18 Varying these 5- year incidence rates for 
secondary malignancies from 0.3% and 1.2% resulted 
in alternative estimates ranging between £2 million and 
£8 million (table 6).
Average productivity losses due to early mortality, long- 
term and short- term absence and secondary malignan-
cies, weighted by age group, are summarised in table 7. 
These estimates also capture differences in wage rates 
and workforce participation as well as the distribution of 
chemotherapy- related deaths and work absence across 
different age groups. Those aged 45–69 years were associ-
ated with a higher proportion of productivity losses.
Total lost productivity from providing informal care 
was estimated at ~£1.1 million. Carers lose over 2 hours 
of employment per week,9 amounting to salary losses of 
£1000 per year. Half of all carers are in full- time or part- 
time employment25 and 36% provide long- term care for 
more than 3 years.26 To account for long- term care, we 
estimated total caregiving costs as £5.8 million, over a 
5- year period of care.
INTERVIEWS WITH PARTICIPANTS
Impact of treatment
Mary and Sue had very different experiences through 
treatment for breast cancer. Mary was offered various 
options for chemotherapy treatment but did not under-
stand all the medical implications and was too emotion-
ally absorbed on the breast cancer to think about 
treatment. Sue was offered a lumpectomy but no other 
choice of treatment, due to the type of cancer she had. 
Both women were emotionally stunned by the situation 
and feared chemotherapy:
…my world fell apart…I felt an emotional wreck, ab-
solutely. At the time when the surgeon told me I just 
cried. Yes, it was an emotional time and I knew I’d got 
to have chemotherapy and radiotherapy. It was very 
emotional, like a roller coaster. (Mary)
They both suffered the same side effects (loss of hair, 
eyelashes, eyebrows, tiredness). However, Sue found 
effects to the alimentary canal very hard to deal with as 
she had constipation and diarrhoea at the same time. 
Loss of taste was her worst side effect as this impacted 
on so much—eating, enjoyment of food, cooking for the 
family:
For three weeks everything tasted of salt, that was 
hard, even water…. then after that I just couldn’t 
taste anything…because your mouth is so dry it af-
fects your textures so I couldn’t eat bread because of 
the texture…you know so that was probably the most 
challenging thing was because you just don’t want 
anything really… (Sue)
For Mary hair loss was the worst side effect and made 
her feel like ‘a patient with cancer’ without her wig and 
makeup:
I get up and look at myself in the mirror, aw, cancer 
patient. OK, have a shower, put my make up on, put 
Table 5 Patient productivity losses—short- term work 
absence
Scenario 
















Table 6 Mortality losses from secondary malignancy under alternative incidence rates
Scenario summary Base case Best case Worst case
5- year incidence of secondary malignancy 0.50% 0.30% 1.20%
Total cost/year £3 364 107 £2 018 464 £8 073 857
Average cost/per person £49 964 £49 964 £49 964
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my wig on – look in the mirror. That’s better, with a 
wig I can cope… (Mary)
Informal care
Close family members supported both women: Mary by 
her daughter, Sue by her husband. The burden of treat-
ment was high on both family members as they attended 
all or most of the sessions. Rose, Mary’s daughter, had irri-
table bowel disease and four children, and Mary had two 
dogs and a cat that needed care. Mary felt the experience 
impacted on her daughter:
My daughter coped very well, she wouldn’t let anyone 
else take me (to hospital) …and only missed two ses-
sions of radiotherapy. Now it’s behind us, I think it’s 
hitting her. She was strong for me… I think she needs 
counselling…. (Mary)
Sue’s children were affected, and her husband worked 
away during the week and so had to take leave and make 
considerable changes to his work pattern to accompany 
his wife to the hospital:
My husband works away during the week and every 
three weeks he is away for two weeks at a time so umm 
he had to obviously go into his work and sort out… 
My daughter was, you know she is quite anxious any-
way so that was quite upsetting, and my son was away 
at Uni so that…you know what it’s like, mums are al-
ways there, and nothing happens to mums. (Sue)
Employment impacts
Both women worked full time in stressful jobs before 
the diagnosis but were treated quite differently. Sue was 
supported throughout and had 6 months’ full pay but had 
to return to work earlier than she would like as her pay 
had dropped to half. She also could not take further leave 
until 2023 due to her government- sector employer’s use 
of a rolling 4- year programme for sickness leave. Mary 
only received 24 weeks’ statutory sick pay, necessitating 
government financial help to just meet her needs:
I’ve gone to the Government. Never had to do it. I 
don’t want to do it. Feel I shouldn’t be doing it. I get 
Universal credit and high- level mobility allowance 
(PIP). I would be up the creek without a paddle. If I 
hadn’t got high- level PIP I’d be £500 short a month. 
My rent is £720 per month. I’ve just had to fight. You 
don’t need the worry and stress on top of cancer. 
(Mary)
Mary had been off work for over a year, and a bout of 
illness and her emotional state have delayed her return 
to work. She is due to retire in 2020 and has decided to 
return to work for 15 hours per week, necessitating relin-
quishing her senior role.
Out-of-pocket expenses
Mary and Sue had one wig each provided by the National 
Health Service and they purchased another. They also 
bought more clothes due to surgery and weight increase. 
Mary paid for permanent eyebrows and Sue purchased 
products for sensitive skin:
I had to buy headscarves and new bras (£15 each). I 
had to buy new clothes…I was recommended to use a 
cream…when I was having chemo to use it like twice 
a day and obviously when radiotherapy and that’s like 
£8 a bottle and I was getting through one of them 
probably every two weeks… You can’t use normal 
shampoo, or body wash because of the perfume…re-
act with your skin because it is delicate. Toothpaste, 
I had to buy baby toothbrushes so that they are very 
soft because of my gums umm yeah so it does affect 
most places really. (Sue)
Other direct costs included trips to the hospital for 
diagnosis treatment—at least 30. There is ongoing treat-
ment for Mary and follow- up checks for both. Mary was 
reimbursed her travel cost, but Sue was not. Overall, treat-
ment for breast cancer adds considerable direct costs to 
the sufferer and the family.
Professionals’ perspectives
The consultant practitioner (CP) sees patients at the time 
of diagnosis and the nurse practitioner (NP) supports 
patients and their families. They both felt that chemo-
therapy should be used selectively for patients who 
need it to improve prognosis, rather than giving it to all 
because of the risk of morbidity such as neutropenia and 
leukaemia, and mortality:
…we had a group of patients who we said ‘you don’t 
need chemo’ and a group of patients where we said 
‘oh we think you should have chemo’ and a big group 
of patients in the middle where we are going ‘umm 
well we think it can have some benefit’ and you sit 
with the patient and go ‘well you know chemotherapy 
may have a role to play and we are not sure but it has 
got its downside and it is horrible. (CP)
They also discussed the psychological impacts of cancer 
and chemotherapy:
…different people cope with it during the four months 
differently but it is unpleasant at the time but you see 
a lot of patients in whom their cognitive function is 
never quite the same afterwards….(CP)
…people will talk about ‘chemo brain’ and after, well 
whilst having chemotherapy and then also some time 
afterwards, it is a real cotton wool head feeling, you 
feel a bit forgetful and I have people even six months 
to a year down the line saying ‘I have still got like this 
chemo brain’ … also their outlook on their career 
and things change as well …. (NP)
The NP confirmed that families often face financial 
costs that include travel and time for treatment, home 
care, childcare and animal care during chemotherapy. 
Changes in work status add to the financial hardship to 
cover living costs:
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…I know one workplace that literally only paid 
six weeks’ full time pay and then three weeks’ half pay 
and then it was Statutory Sick Pay and you imagine if 
you’re having your chemo like say five to six months 
of treatment and you are out of work for that amount 
of time because…you physically can’t work, then, 
and you have got a mortgage to pay, you may have 
a car that you are paying off and you have got kids 
at school, you have got childcare you know the cost 
implication in chemotherapy for patients and their 
welfare side is, is huge… (NP)
The NP reported the need for counselling long after 
cancer treatment:
…we do a lot of counselling for children that have 
seen their parents go through chemotherapy and I 
know one of my breast cancer patients….she is a few 
years ago post- treatment but her son is now being af-
fected by the fact that she had to have chemotherapy 
…he… keeps still seeing his mum without hair …he 
is worried about the cancer coming back now… … 
all these thoughts are now coming back to him. (NP)
DISCUSSION
This analysis demonstrates that use of chemotherapy for 
the treatment of early breast cancer imposes substantial 
and far- reaching costs well beyond those associated with 
the actual treatment itself. The greatest burden accrued 
to society from patient productivity losses. Patient out- of- 
pocket expenses and costs of informal care were smaller 
by comparison but nevertheless significant. The partici-
pants who had been through the chemotherapy process 
for early- stage breast cancer emphasised these costs to 
themselves and their informal carers. These findings 
support research in the USA, showing the real finan-
cial burden to patients, where over one- third of patients 
worried about the costs and reduced food purchases and 
one- fifth had lost their homes.27 The healthcare system 
is different in the USA and patients often have to pay for 
treatment, nevertheless, not being able to work to pay 
daily household bills affected both women interviewed 
for this research. In addition, interviews with participants 
and health practitioners highlighted that the psycholog-
ical aspects of chemotherapy ripple through the social 
world of patients with breast cancer, often with long- 
lasting effects.
To our knowledge, this was the first study providing cost 
estimates attributable specifically to the use of chemo-
therapy for early breast cancer in the UK. Other published 
studies have looked more generally at the overall costs 
associated with breast cancer. These suggest that early 
mortality costs for breast cancer in the UK fall between 
£307.9 million and £8968 million,6–8 while morbidity- 
related costs arising from work absence have been esti-
mated to be between £59 million and £184.8 million.6 8 
Estimates for the costs of informal caregiving for patients 
with breast cancer range between £115.9 million and 
£309 million.6 8
Our estimates are comprehensive, and we examined 
different approaches to estimating informal care costs. 
The base case involved productivity losses associated 
with time taken off work by carers. However, to capture 
the additional impact on emotional well- being, which is 
recognised but not widely measured in monetary terms, 
we conducted a secondary analysis using a well- being 
valuation method.28 Further research is needed to under-
stand the impacts of emotional and psychological effects 
on patients, as raised in the interviews, and the associated 
societal costs.
Long- term mortality costs were limited to those asso-
ciated with incidence of acute myeloid leukaemia and 
myelodysplastic syndrome since these are frequently 
reported following chemotherapy use. Accounting for 
a fuller range of relevant malignancies and events may 
generate higher estimates. Out- of- pocket costs were based 
on a large patient survey detailing different cost compo-
nents for all types of patients with cancer and reporting 
average costs per month and the proportion of patients 
facing these additional costs.29 Our estimations necessi-
tated assumptions about what expenses could reasonably 
be attributed to chemotherapy for breast cancer and, 
although we tested the impact of these through sensitivity 
analyses, data specifically for the target population would 
likely generate more robust estimates.
More generally, we acknowledge that COI estimates 
such as these are only able to identify the consequences of 
an illness and attach monetary valuations.30 They do not 
convey information on related outcomes or efficiency and 
may present estimation and interpretation challenges.25 
However, understanding the overall burden of an illness 
serves several important uses.30 They can help identify 
the main cost components and their incidence; describe 
the relative magnitude of overall costs at national level 
and explain variability of costs (eg, by disease severity, 
demographic and socioeconomic factors). This can then 
help decision makers prioritise spending and better plan 
future service provision.31
CONCLUSION
While medical need will ultimately drive individual- level 
treatment decisions, our demonstration of the size and 
extent of costs falling beyond healthcare suggest that 
treatment and commissioning decisions for adjuvant 
chemotherapy need to incorporate a much fuller consid-
eration of benefits, harms and wider costs. These wider 
costs and societal perspective should be considered in 
commissioning guidelines so as to ensure chemotherapy 
is better targeted at those who most need it and to avoid 
placing unnecessary costs on patients, their caregivers 
and wider society.
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